Neuroscientists rapidly decode interoception, the long-overlooked links between our brain and the heart, stomach and other organs.
The future of autism spectrum disorders looks brighter, thanks to rapid advances in genomic sequencing technology and progress toward targeted, precision medicines.
How the Lottie French Lewis Fund supports early careers and Alzheimer’s research.
Advances in digital health technologies allow for continuous monitoring of behavioral and physiological metrics, such as heart rate, blood sugar, activity and sleep. Being able to collect longitudinal data on study participants gives scientists much more detailed insights into how their bodies are responding to any given intervention, enabling a more individualized approach to medicine.
The beauty of science is that it can fulfill all these aspirations. The drive to understand nature—to decipher its most complex and elusive facets—provides the fresh, new ideas we need to overcome our greatest problems. Hard-won scientific knowledge is a powerful tool for improving people’s lives.
Ozanimod, the drug invented at Scripps Research that won FDA approval last year for relapsing forms of multiple sclerosis, has been approved in the United States for a second high-need medical condition, ulcerative colitis.
Pioneering biochemist has been awarded a $3 million Breakthrough Prize for transformative advances in the understanding of neurological disease.
The American Crystallographic Association has recognized Goodsell's “contributions to crystallographic research by one who is known to be an effective teacher of crystallography.”
Roberts co-invented ozanimod (Zeposia®) with Scripps Research professor Hugh Rosen, MD, PhD, and their laboratory colleagues.
In giving the honor, the institute said Cravatt’s work has “radically changed the standards of proteomics, resulting in innovative solutions to the creation of modern medicines.”
The role recognizes a researcher who has made a significant contribution to a natural products-related area of the chemical sciences in their early independent career.
The Royal Society of Chemistry has recognized Karl Barry Sharpless, PhD, and his team, along with their collaborators, for their development of a technology called “multidimensional click chemistry,” that has opened up new possibilities in biomedicine, materials science and other fields.
Kelly receives the honor for his seminal work on transthyretin and its contributions to the amyloid hypothesis.
The Donald E. and Delia B. Baxter Foundation has named Michael Constantinides, PhD, winner of its 2021 Young Investigator Award.
Calibr, the drug discovery division of Scripps Research, is home to ReFRAME, the world’s leading collection of drugs known to be safe in humans. During the COVID-19 pandemic, the institute combed this collection to identify medicines that could be rapidly repurposed against the novel coronavirus.
A $24 million grant will support Calibr in leveraging innovative approaches to address some of the most challenging neglected tropical diseases across the globe.
Protein engineering, autism genetics and virology experts join the faculty, and a Scripps Research Fellow is promoted to assistant professor, in pursuit of new knowledge and treatments for unmet medical needs.